The in vivo efficacies of amikacin, ceftazidime, and their combination were evaluated in experimental aortic valve endocarditis due to Pseudomonas aeruginosa. Eighty catheterized rabbits were infected with a P. aeruginosa strain susceptible to both amikacin and ceftazidime and then received no therapy (controls), amikacin (15 mg/kg per day), ceftazidime (100 mg/kg per day), or amikacin-ceftazidime. Amikacin Morrison, Chemotherapy [Basel], in press). In that study, the amikacin-ceftazidime regimen was significantly more effective than the single-drug regimens in reducing the mean vegetation titers of P. aeruginosa and reducing the prevalence of bacteriologic relapses after therapy was terminated. In the current study, we examined this synergistic combination in experimental left-sided P. aeruginosa endocarditis, the most refractory syndrome in human cases (16 identification, serotyping, and resistance to rabbit serum have been previously described (5).
Studies of human infective endocarditis caused by Pseudomonas aeruginosa have emphasized the difficulties in achieving cures with antibiotic therapy alone, with treatment failures of 35 to 75% (15) (16) (17) . A major problem in this regard has been the development of resistance in vivo to the antibiotics commonly used for this infection (e.g., 3-lactams and aminoglycosides), resulting in refractory or recrudescent bacteremia and endocarditis (15) (16) (17) . This phenomenon has been most frequently observed when there was involvement of left-sided cardiac valves (16) .
Bayer et al. have recently reported the excellent in vivo responses of experimental tricuspid valve endocarditis due to P. aeruginosa to combination chemotherapy with amikacin-ceftazidime (A. S. Bayer, K. Lam, D. C. Norman, K. S. Kim, and J. 0. Morrison, Chemotherapy [Basel] , in press). In that study, the amikacin-ceftazidime regimen was significantly more effective than the single-drug regimens in reducing the mean vegetation titers of P. aeruginosa and reducing the prevalence of bacteriologic relapses after therapy was terminated. In the current study, we examined this synergistic combination in experimental left-sided P. aeruginosa endocarditis, the most refractory syndrome in human cases (16) .
(This investigation was presented in part at the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, Nev., 24 to 26 October 1983 [abstr. no. 370].)
MATERIALS AND METHODS Organism. The P. aeruginosa strain used in this study (P. aeruginosa PA-96) was a clinical isolate that had been used in a prior study of experimental endocarditis (5) . Its * Corresponding author.
identification, serotyping, and resistance to rabbit serum have been previously described (5) .
Antibiotic susceptibility testing. MICs and MBCs of amikacin and ceftazidime were determined by the broth macrodilution technique (13) with Mueller-Hinton broth (MHB; BBL Microbiology Systems, Cockeysville, Md.). MHB has a concentration of 0.5 mg/100 ml of magnesium and 3.2 mg/100 ml of calcium. Logarithmic-growth-phase cultures were used to prepare inocula of PA-96 at -5 x 105 or -5 x 107 CFU/ml. The -107 inoculum was utilized to determine the antibiotic susceptibility at bacterial densities likely to be encountered within cardiac vegetations in vivo (1) . The MIC was defined as the lowest antibiotic concentration causing no visible turbidity. The MBCs were determined by subculturing 10 ,ul from each clear tube onto antibiotic-free MH agar plates. The MBC was the lowest concentration of antibiotic that effected -99.9% reduction of the original inoculum. The MICs and MBCs of selected amikacin-or ceftazidime-resistant organisms isolated from endocardial vegetations were also determined for gentamicin, kanamycin, moxalactam, cefoperazone, azlocillin, mezlocillin, and ciprofloxacin (inoculum size, -5 x 105 CFU/ml).
In vitro bactericidal interaction testing. Bactericidal interactions of ceftazidime and amikacin against PA-96 were examined with the time-kill assay system. As before, a logarithmic-phase inoculum of either -5 x 105 or -5 x 107 CFU/ml was used. The final antibiotic concentrations tested were amikacin alone at one-half the MBC, ceftazidime alone at one-half the MBC, or amikacin-ceftazidime, each drug at one-quarter its MBC. A synergistic interaction was considered present when the amikacin-ceftazidime combination caused a -2 log10 decrease in CFU per milliliter at 24 h in comparison with the more active single agent (10) .
Induction and treatment of P. aeruginosa endocarditis. Eighty female New Zealand White rabbits, weighing 2 to 2.5 kg each, were anesthetized with 50 mg of ketamine hydrochloride given intramuscularly (Bristol Laboratories, Syracuse, N.Y.). The left ventricle was catheterized with a polyethylene catheter by passing the catheter tip across the aortic valve as previously described (1) . The catheter remained in place for the duration of the study. Each animal was inoculated intravenously with -108 CFU of PA-96 24 h after catheterization. Positive blood cultures for P. aeruginosa at 24 h postinoculation were taken as presumptive evidence of endocarditis (1) . Macroscopic and bacteriologic data acquired at the time of sacrifice provided ultimate confirmation of vegetative endocarditis.
The 80 rabbits were randomized (by computer-generated code) to one of four therapy groups of 20 rabbits each: untreated controls, amikacin at 15 mg/kg per day (intramuscularly, in two divided doses-8 a.m. and 5 p.m.), ceftazidime at 100 mg/kg per day (intramuscularly, in two divided doses-8 a.m. and 5 p.m.), and amikacin-ceftazidime at the above dosages and schedules. Therapy was begun 48 h after inoculation. The above regimens were identical to those that produced an excellent in vivo response in a previous study on experimental tricuspid valve endocarditis produced by the same P. aeruginosa strain (PA-96 [2a] ). Pilot studies in our laboratory indicated that these dosage regimens consistently produced supra-MBC serum levels at -1 h postinjection.
Sacrifice of animals. Animals were sacrificed by rapid intravenous injection of 150 mg of sodium pentobarbital on either day 7 or 14 of therapy or on day 5 after stopping therapy (to determine bacteriologic relapse). At sacrifice, aortic valve vegetations were individually excised and weighed. Each vegetation was homogenized in MHB and quantitatively subcultured as previously described (5) . No attempt was made to inactivate amikacin or ceftazidime in vegetation homogenates, as sacrifices were performed at least 18 h after the last drug dose (18) . Animals that had been dead longer than 6 h before postmortem examination were excluded from bacteriologic evaluation (18) . Portions of each homogenate were also subcultured onto MH agar containing 50 p,g of either ceftazidime or amikacin per ml (depending on the therapeutic regimen) to detect in vivo development of resistance. Concentrations of 50 ,ug/ml were chosen because they were at or above the breakpoints for resistance of either agent (.32 ,ug/ml [11] ). In calculating mean titers, culturenegative vegetations were considered to contain c2 log1o CFU/g based on average vegetation weight (0.01 g [3] ). To delineate the relative proportions of antibiotic-resistant and antibiotic-susceptible isolates contained within individual vegetations, a resistance ratio was calculated (4). This is defined as the log1o of the ratio of the number of resistant organisms to the total number of organisms within a vegetation [log1o (number of resistant isolates per total number of isolates)].
In vitro passage studies. Stabilities of antimicrobial resistances induced in vivo were determined by in vitro passage experiments. Two ceftazidime-resistant and two amikacinresistant P. aeruginosa variants, isolated from vegetations of animals receiving the respective single agents, were studied. Each strain was grown in antibiotic-free MHB overnight and then parallel plated onto both antibiotic-free and antibioticcontaining MH agar (50 ,g of amikacin or ceftazidime per ml, depending on the therapy group). The serial passage of each strain in antibiotic-free MHB, with parallel plating as above, was performed an additional 14 times.
Concentrations of antibiotics in serum. On day 3 of antibiotic treatment, blood was drawn 1 h after drug administration and just before the next dose of antibiotic for measurement of near peak and trough concentrations in serum, respectively. Amikacin levels in serum were determined by a radioimmunoassay technique (American Diagnostics Corp., Newport Beach, Calif. [9] ); ceftazidime levels in serum were determined by high-pressure liquid chromatography (8) . The sensitivities of these assays are 0.5 p,g/ml for amikacin and 5 ,ug/ml for ceftazidime.
Serum bactericidal titers (SBTs). All SBTs were determined by the microtiter method (14) in sera obtained at the 1-h posttreatment period referred to above. The diluent was heat-inactivated (at 56°C for 30 min), freshly pooled, normal rabbit serum. The serum bactericidal titer was defined as the highest serum dilution causing .99.9% killing of the original inoculum (14) .
Cross-resistance. To determine whether there was crossresistance to ceftazidime and amikacin, P. aeruginosa variants cultured on antibiotic-containing plates were replica plated (6) onto agar containing the opposite single drug (e.g., ceftazidime at 50 ,ug/ml). (ii) Blood cultures. Blood cultures taken 24 h after inoculation were positive for P. aeruginosa in all 80 catheterized animals, presumptively confirming induction of endocarditis (1) . Blood cultures taken at time of sacrifice were uniformly positive in control animals and remained positive in 89% of the recipients of amikacin monotherapy. In contrast, terminal blood cultures were positive in only 19 and 20% of the recipients of ceftazidime either alone or in combination with amikacin, respectively. The frequencies of positive blood cultures in the latter two therapy groups were significantly lower than those observed in controls or animals receiving amikacin alone (P < 0.0005).
(iii) Titers of P. aeruginosa in endocardial vegetations. All vegetations from untreated controls (n = 15) yielded P. aeruginosa on culture (no spontaneous cures). The range of titers for these controls was similar to that previously cited in this model (1). On day 7 of therapy, titers for the rabbits treated with amikacin-ceftazidime were significantly lower than those for amikacin-or ceftazidime-treated groups (P < 0.0005, Table  1 ). On day 14, mean vegetation titers of recipients of the combination regimen were significantly higher than those on day 7 (P < 0.0005).
On day 5 after termination of treatment, the mean vegetation titers of all three treated groups were high (>1og10 9) and not significantly different from those of untreated controls sacrificed earlier.
(iv) Development Replica-plating studies provided no evidence for crossresistance, indicating' that development of resistance to ceftazidime or amikacin was an independent event requiring exposure to the drug.
Antibiotic levels. Amikacin and ceftazidime levels in serum at 1 h postdosage equaled or exceeded the MBC of PA-96 determined in vitro for both i05 and 107 inocula ( mirrored by the results of in vitro studies which showed that amikacin resistance was lost and ceftazidime resistance was retained during serial transfer through drug-free media. The in vitro and in vivo stability of ceftazidime resistance suggested that these variant strains of P. aeruginosa might represent stably derepressed mutants as described by Sanders and Sanders (19) . (vi) Neither amikacin nor ceftazidime resistances were limited to these inducing antibiotics but were common to other structurally related compounds. (vii) The in vivo development of resistance to amikacin or ceftazidime did not cross antibiotic class lines; th,us, resistant mutants induced by ceftazidime monotherapy did not manifest amikacin resistance on crossover replica-plating studies nor did aminoglycoside-resistant mutants induced by amikacin monotherapy manifest ceftazidime resistance.
It is not entirely clear why amikacin-ceftazidime therapy resulted in both treatment failures and development of antibiotic resistances in vivo in left-sided endocarditis, when the identical treatment regimen exerted such a potent in vivo effect in right-sided endocarditis due to the same strain without development of resistances in vivo (2a). The only readily identifiable difference in these two model systems is that P. aeruginoSa titers in aortic valve vegetations are -2 log1o higher than those seen in tricuspid valve vegetations (1, 2a, 5) ; this may relate to enhanced pseudomQnal growth under conditions of higher oxygen tensions as seen on the left side versus the right side of the heart (20) . These disparate results in the therapy of right-versus left-sided P. aeruginosa endocarditis 'models vis-a-vis efficacy and development of resistance may represent an in vivo inoculum effect (7, 21 
